The power of healthcare data gives rise to novel markers of cardiovascular disease and stroke in the earliest, preventable stages CHICAGO, Nov.11, 2018 — Developing novel approaches to understand cardiovascular health and pre-disease is the cornerstone strategy of One Brave Idea™, a research initiative led by Dr. Calum MacRae, vice chair for Scientific Innovation in the department of Medicine at Brigham …
Cleveland HeartLab and Quest Diagnostics Forming Base for Quest’s National Cardiometabolic Center of Excellence
– Cleveland HeartLab to be the base for Quest’s first national center of excellence in cardiometabolic disorders, with a focus on services that help patients and physicians nationwide identify hidden risks of heart disease – Relationship to establish a strategic collaboration to identify and offer diagnostic services from Cleveland Clinic’s innovations in inflammation and other areas of medicine SECAUCUS, N.J. and …
Cleveland HeartLab Launches Only Clinical Test for Measuring TMAO, an Important Measure of Gut Dysfunction that is Associated with Cardiovascular Disease Risk
Download Press Release Innovative new test published in The New England Journal of Medicine detects levels of TMAO – which, when elevated, correlates with a two-fold increased risk of heart attack or stroke February 16, 2016, CLEVELAND: Cleveland HeartLab Inc., the premier cardiovascular disease management company, announced it has successfully developed, validated and launched a new clinical test for the assessment of …
Cleveland HeartLab Partnering with Procter & Gamble and Cleveland Clinic to Advance Discovery in Heart Disease with TMAO Testing
Link to Press Release Corporate Communications 9500 Euclid Ave. / JJN4-01 Cleveland, OH 44195 Phone: 216.444.0141 Fax: 216.445.3040 clevelandclinic.org/newsroom Contacts: Cleveland Clinic: Robert Smith, 216.385.6179, smithr5@ccf.org P&G: Michelle Vaeth, 513-622-4727, vaeth.m@pg.com Cleveland HeartLab: Bethany Hilt, 330-338-6633, bethany.hilt@gmail.com CLEVELAND CLINIC PARTNERING WITH PROCTER & GAMBLE AND CLEVELAND HEARTLAB TO ADVANCE DISCOVERY IN HEART DISEASE The Partners Will Build Upon …
Journal of Medical Economics – CHL testing could reduce events by 10%, saving $187 Million
Link to Press Release New Study Shows Cleveland HeartLab Inflammation Testing can Prevent Thousands of Heart Attacks and Strokes, Averting $187 Million in Healthcare Costs for Cardiovascular Disease—The Number One Killer of Men and Women in the U.S The American Heart Association estimates 50 percent of all heart attacks and strokes occur in individuals with normal cholesterol. Cleveland HeartLab’s inflammation …